hepatitis B vaccine (recombinant) pediatric/adolescent 20 MCG in 0.5 ML Injection
SY
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
hepatitis B surface antigen vaccine 20 MCG in 0.5 ML Injection
PSN
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
hepatitis B surface antigen vaccine 20 MCG per 0.5 ML Injection
SY
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
hepatitis B surface antigen vaccine 0.04 MG/ML per 0.5 ML Injection
SY
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017
0.5 ML hepatitis B surface antigen vaccine 0.04 MG/ML Injection
SCD
10
These highlights do not include all the information needed to use HEPLISAV-B ® safely and effectively. See full prescribing information for HEPLISAV-B. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] injection, for intramuscular use Initial U.S. Approval: 2017